|

Disitamab Vedotin (RC48-ADC) in Breast Cancer

RECRUITINGSponsored by RenJi Hospital
Actively Recruiting
SponsorRenJi Hospital
Started2023-06-01
Est. completion2027-03
Eligibility
Healthy vol.Accepted
View on ClinicalTrials.gov →

NCT05851677

Summary

To evaluate the efficacy and safety of Disitamab vedotin (RC48-ADC) in patients with breast cancer.

Eligibility

Healthy volunteers accepted
Inclusion Criteria:

* Histologically confirmed breast cancer;
* Prior or current use of Disitamab vedotin (RC48-ADC);

Exclusion Criteria:

* Participating in clinical trials involving Disitamab vedotin (RC48-ADC) or not.

Conditions2

Breast CancerCancer

Browse More Trials

Cancer trialsBreast Cancer trials

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.